252 related articles for article (PubMed ID: 19157637)
1. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
Haas C; Krinner E; Brischwein K; Hoffmann P; Lutterbüse R; Schlereth B; Kufer P; Baeuerle PA
Immunobiology; 2009; 214(6):441-53. PubMed ID: 19157637
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
[TBL] [Abstract][Full Text] [Related]
3. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110.
Witthauer J; Schlereth B; Brischwein K; Winter H; Funke I; Jauch KW; Baeuerle P; Mayer B
Breast Cancer Res Treat; 2009 Oct; 117(3):471-81. PubMed ID: 18819003
[TBL] [Abstract][Full Text] [Related]
4. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
[TBL] [Abstract][Full Text] [Related]
5. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
6. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
Cioffi M; Dorado J; Baeuerle PA; Heeschen C
Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
[TBL] [Abstract][Full Text] [Related]
7. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
[TBL] [Abstract][Full Text] [Related]
9. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
10. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
[TBL] [Abstract][Full Text] [Related]
12. Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal.
Tamang DL; Redelman D; Alves BN; Vollger L; Bethley C; Hudig D
Cytokine; 2006 Nov; 36(3-4):148-59. PubMed ID: 17188506
[TBL] [Abstract][Full Text] [Related]
13. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
14. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
Brandl C; Haas C; d'Argouges S; Fisch T; Kufer P; Brischwein K; Prang N; Bargou R; Suzich J; Baeuerle PA; Hofmeister R
Cancer Immunol Immunother; 2007 Oct; 56(10):1551-63. PubMed ID: 17310380
[TBL] [Abstract][Full Text] [Related]
15. The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture.
Hoh A; Dewerth A; Vogt F; Wenz J; Baeuerle PA; Warmann SW; Fuchs J; Armeanu-Ebinger S
Liver Int; 2013 Jan; 33(1):127-36. PubMed ID: 23088518
[TBL] [Abstract][Full Text] [Related]
16. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Hoffmann P; Hofmeister R; Brischwein K; Brandl C; Crommer S; Bargou R; Itin C; Prang N; Baeuerle PA
Int J Cancer; 2005 May; 115(1):98-104. PubMed ID: 15688411
[TBL] [Abstract][Full Text] [Related]
17. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
[TBL] [Abstract][Full Text] [Related]
18. Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets.
Smyth MJ; Norihisa Y; Ortaldo JR
J Immunol; 1992 Jan; 148(1):55-62. PubMed ID: 1345790
[TBL] [Abstract][Full Text] [Related]
19. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
20. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).
Riesenberg R; Buchner A; Pohla H; Lindhofer H
J Histochem Cytochem; 2001 Jul; 49(7):911-7. PubMed ID: 11410615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
